<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377048</url>
  </required_header>
  <id_info>
    <org_study_id>202001045MIPA</org_study_id>
    <nct_id>NCT04377048</nct_id>
  </id_info>
  <brief_title>Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer</brief_title>
  <official_title>Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACT Genomics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assumes that to achieve significant therapeutic efficacy in advanced pancreatic&#xD;
      cancer with immunotherapy, the immune system must remain relatively intact. Therefore, early&#xD;
      use, low tumor load, adequate organ function, and slow growth of the tumor are the key&#xD;
      points. Stage IV pancreatic adenocarcinoma patients with limited metastatic lesions and&#xD;
      adequate organ function will be enrolled. Gemcitabine plus S-1 (GS) will be administered&#xD;
      initially, and then CA 19-9 will be evaluated. Those fulfilling pre-defined criteria of CA&#xD;
      19-9 will receive nivolumab add-on therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Simon's two-stage design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>overall response rate of gemcitabine/S-1/nivolumab</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab/GS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part-1: GS Induction&#xD;
Patients will receive GS for 1 cycle.&#xD;
S-1: 60/80/100 mg per day (based on body surface area, BSA); D1-12; 3 weeks per cycle&#xD;
BSA &lt; 1.25 m2: 60 mg/day; 1.25 m2 ≤ BSA &lt; 1.5 m2: 80 mg/day; BSA ≥ 1.5 m2: 100 mg/day&#xD;
Gemcitabine: 850 mg/m2; D1, 8; 3 weeks per cycle&#xD;
After GS, patients fulfilling the pre-defined CA 19-9 criteria will enter the Add-On part.&#xD;
Part-2: Nivolumab Add-On&#xD;
Nivolumab: 3 mg/kg every 2 weeks, 6 weeks per cycle&#xD;
S-1: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle&#xD;
Gemcitabine: according to the individualized dose on D8 of cycle 1 in Part-1, 6 weeks per cycle&#xD;
The treatment will be continued until disease progression, intolerance to study treatment or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>as described in &quot;NGS Arm&quot;</description>
    <arm_group_label>Nivolumab/GS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>as described in &quot;NGS Arm&quot;</description>
    <arm_group_label>Nivolumab/GS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-Gimeracil-Oteracil</intervention_name>
    <description>as described in &quot;NGS Arm&quot;</description>
    <arm_group_label>Nivolumab/GS</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histologically proven pancreatic adenocarcinoma&#xD;
&#xD;
          2. newly diagnosed, stage IV pancreatic cancer with limited metastases and tumor burden&#xD;
&#xD;
          3. no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, local&#xD;
             therapy (eg. radiofrequency ablation, irreversible electroporation, etc.),&#xD;
             immunotherapy, cell therapy (autologous or allogenic) used for pancreatic cancer&#xD;
&#xD;
          4. presence of at least one measurable lesion at the pancreas and at least one measurable&#xD;
             metastatic lesion&#xD;
&#xD;
          5. age between 20 and 75 years at registration&#xD;
&#xD;
          6. ECOG performance status of 0 or 1&#xD;
&#xD;
          7. adequate major organ functions&#xD;
&#xD;
          8. baseline CA 19-9 &gt; upper limit of normal&#xD;
&#xD;
          9. Glasgow prognostic score of 0 (ie. albumin ≥ 3.5 g/dL and CRP ≤ 1 mg/dL)&#xD;
&#xD;
         10. ability to take study medication (S-1) orally&#xD;
&#xD;
         11. no clinically significant abnormal ECG findings within 28 days prior to registration&#xD;
&#xD;
         12. Women of childbearing potential (including women with chemical menopause or no&#xD;
             menstruation for other medical reasons) must agree to use contraception from the time&#xD;
             of informed consent until 5 months or more after the last dose of investigational&#xD;
             products. Also, women must agree not to breastfeed from the time of informed consent&#xD;
             until 5 months or more after the last dose of the investigational product.&#xD;
&#xD;
         13. Men must agree to use contraception from the start of study treatment until 7 months&#xD;
             or more after the last dose of the investigational product.&#xD;
&#xD;
         14. Sign written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected treatment-related pulmonary toxicity within 28 days prior to&#xD;
             registration&#xD;
&#xD;
          2. presence of diarrhea ≥ CTCAE v.5.0 grade 2&#xD;
&#xD;
          3. concomitant systemic infection requiring treatment&#xD;
&#xD;
          4. clinically significant co-morbid medical conditions, including cardiovascular disease&#xD;
             known autoimmune disease&#xD;
&#xD;
          5. concurrent autoimmune disease or history of chronic or recurrent autoimmune disease&#xD;
&#xD;
          6. prior organ allograft or allogeneic bone marrow transplantation&#xD;
&#xD;
          7. received systemic corticosteroids (except for temporary use, e.g., for examination or&#xD;
             prophylaxis of allergic reactions) or immunosuppressants within 28 days before&#xD;
             registration&#xD;
&#xD;
          8. HBV (positive HBsAg or HBV DNA) or HCV carrier (positive anti-HCV or HCV RNA)&#xD;
&#xD;
          9. known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome&#xD;
&#xD;
         10. moderate or severe ascites, pleural effusion, or pericardial effusion requiring&#xD;
             treatment&#xD;
&#xD;
         11. central nervous system metastasis&#xD;
&#xD;
         12. prior or concurrent malignancies within the last 3 years, with the exception of&#xD;
             carcinoma in situ of the cervix, or basal type skin cancer&#xD;
&#xD;
         13. concomitant treatment with flucytosine, phenytoin or warfarin&#xD;
&#xD;
         14. any major surgery within 4 weeks of study treatment. Participants must have recovered&#xD;
             from the effects of major surgery or significant traumatic injury at least 14 days&#xD;
             before the first dose of study treatment.&#xD;
&#xD;
         15. transfusion from 72 hours prior to registration to the first dose of study drug&#xD;
             administration&#xD;
&#xD;
         16. pregnant women or nursing mothers, or positive pregnancy tests&#xD;
&#xD;
         17. severe mental disorder&#xD;
&#xD;
         18. treatment with botanical preparations (eg, herbal supplements or traditional Chinese&#xD;
             medicines) intended for general health support or to treat the disease under study&#xD;
             within 2 weeks prior to registration&#xD;
&#xD;
         19. vaccine therapies for prevention of infectious diseases within 4 weeks of study drug&#xD;
             administration except inactivated seasonal influenza vaccine&#xD;
&#xD;
         20. any condition requiring anti-platelet or anticoagulant therapy within 12 weeks prior&#xD;
             to registration&#xD;
&#xD;
         21. oral or iv antibiotic use within 2 weeks prior to registration&#xD;
&#xD;
         22. uncontrollable pain caused by a tumor&#xD;
&#xD;
         23. receiving antineoplastic agents within 28 days before registration&#xD;
&#xD;
         24. patients judged by the principal investigator or subinvestigators to be inappropriate&#xD;
             as subjects of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Hung Yang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shu-Ling Wu</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>67573</phone_ext>
    <email>shulingwu.ntuh@gmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.</citation>
    <PMID>23547081</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018 Feb;36(1):96-102. doi: 10.1007/s10637-017-0525-1. Epub 2017 Nov 8. Erratum in: Invest New Drugs. 2019 Aug;37(4):797.</citation>
    <PMID>29119276</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

